SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
June 4, 2020
 · 
19 min read
 · 
Chelsea Weidman Burke, M.S.
Policy
Biopharma Update on the Novel Coronavirus: June 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.
June 4, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent
Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020.
June 3, 2020
 · 
3 min read
 · 
Gail Dutton
Drug Development
LabCorp Launches Website to Connect Patients with COVID-19 Clinical Trials
The company announced its Covance drug development business was launching COVID-19 Clinical Trial Connect in the U.S. to help people find information on taking part in clinical trials related to COVID-19.
June 3, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 3
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 3, 2020.
June 3, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
After Failure of Earache Drug, Novus Therapeutics Seeks Strategic Alternatives
Novus Therapeutics announced that its Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet its primary endpoint.
June 2, 2020
 · 
3 min read
 · 
Mark Terry
BioForest
Clinical Catch-Up: May 25-29
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
May 29, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
Following Phase II Failure, Ironwood and AbbVie Halt Development of Delayed-Release Linzess
Ironwood and AbbVie said a Phase II trial assessing the drug candidate MD-7246, a delayed-release formulation of Linzess, did not meet its primary or key secondary endpoints.
May 29, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: June 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
May 28, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Startup ViralClear Drives Antiviral into Phase II for COVID-19 Following Significant Preclinical Results
ViralClear Chief Executive Officer Nick Spring told BioSpace that the preclinical work is “telling a very good story.”
May 28, 2020
 · 
3 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Drug Development
Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients
February 29, 2024
 · 
5 min read
Drug Development
Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer’s Disease
February 29, 2024
 · 
10 min read
Drug Development
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
February 28, 2024
 · 
7 min read
Drug Development
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus
February 28, 2024
 · 
6 min read
Drug Development
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
February 28, 2024
 · 
9 min read
Drug Development
The promising results of a phase II clinical study for Akeso’s Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research
February 28, 2024
 · 
6 min read
Drug Development
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
February 28, 2024
 · 
4 min read
Drug Development
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
February 27, 2024
 · 
6 min read
Drug Development
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
February 27, 2024
 · 
4 min read
Drug Development
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
February 27, 2024
 · 
11 min read
Drug Development
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
February 27, 2024
 · 
14 min read
Drug Development
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
February 26, 2024
 · 
6 min read
Drug Development
BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062
February 26, 2024
 · 
4 min read
Drug Development
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
February 26, 2024
 · 
9 min read
Drug Development
XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation
February 26, 2024
 · 
5 min read
Drug Development
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
February 26, 2024
 · 
6 min read
Drug Development
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024
 · 
7 min read
Drug Development
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024
 · 
15 min read
Drug Development
Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
February 25, 2024
 · 
4 min read
Drug Development
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024
 · 
9 min read
Load More